BookArmin Ghobadi, John F. DiPersio, editors.
Summary: Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.
Contents:
The History of Cellular Therapies
Basics of Immunity
Biology of CAR T cells
Cell types used for CAR generation
Combination therapeutics with CART cell therapy
Safety switches used for cellular therapies
Off-the-shelf CAR-T
Manufacturing of CAR-T Cells: the Assembly Line
Navigating Regulations in Gene and Cell Immunotherapy
Bringing CAR-T to the Clinic
CAR T-Cell Complications
Mechanisms of Resistance and Relapse after CAR T cell therapy
Tumor infiltrating lymphocytes (TIL): from bench to bedside
T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic
Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside
Biology of NK cells and NK cells in clinic
Biology and Clinical Evaluation of T/NK Cell Engagers
Roadmap for Starting an Outpatient Cellular Therapy Program.